MUNICH, July 3, 2025 /PRNewswire/ -- According to Yole's Thermal Imaging and Sensing 2024 Market and Technology Report, Teledyne Flir, Raytron, Hikmicro, Lynred, and Seek...
New York City, NY, July 03, 2025 (GLOBE NEWSWIRE) -- In 2025, Nixol, a plant-based dietary supplement, made its debut in the United Kingdom and Ireland, marking a significant entry into the wellness supplement market. Designed to support healthy weight management, boost metabolism, and curb cravings, Nixol has positioned itself as a natural, vegan-friendly alternative to traditional weight loss solutions. Unlike products that rely on synthetic stimulants or restrictive diets, Nixol leverages a blend of carefully selected, science-backed ingredients to promote sustainable fat reduction and overall well-being. This article provides an in-depth exploration of Nixol’s launch, its formulation, claims, scientific backing, customer feedback, and the broader context of its market entry, while critically examining its potential effectiveness and limitations. Visit Official Website
SINGAPORE, July 3, 2025 /PRNewswire/ -- CDNetworks, the APAC-leading network to deliver edge as a service, today announced that Petrolimex Aviation, a major provider of...
HSINCHU, July 3, 2025 /PRNewswire/ -- Gwo Xi Stem Cell Applied Technology Co., Ltd. (TPEx: 6704) is a clinical-stage cell therapy company headquartered in...
BEIJING, SHANGHAI and BOSTON, July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND)...
ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...
The sleep apnea market growth is driven by rising awareness, technological advancements, and demand for personalized care. Companies innovate therapies and solutions for better...
Raw Garden celebrates 10 years with July 4th – 7/10 deals, Sprout promos, and events statewide — highlighting clean cannabis and SF Hash Week activations.
DENVER, July 02, 2025 (GLOBE NEWSWIRE) -- Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has received confirmation from The Nasdaq Stock Market that the Company has evidenced compliance with the minimum $2.5 million stockholders’ equity requirement and all other applicable criteria for continued listing on The Nasdaq Capital Market. Accordingly, the previously disclosed listing matter has been closed.
PITTSBURGH, July 2, 2025 /PRNewswire/ -- EQT Corporation (NYSE: EQT) plans to issue its second quarter financial and operating results news release after market...
Brings 25 years of commercial, product management and engineering leadership at Fortune 100 companies and other innovative technology firms
MESA, Ariz., July 2, 2025 /PRNewswire/...